Our Pipeline

We’re focused on the innovative application of science and medicine

With patients at the center of everything we do, Sunovion has charted new paths to life-transforming treatments that reflect our ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurologic and respiratory disorders.

Candidate Indication/Target Phase
006 Ulotaront (SEP-363856) Schizophrenia Phase 3
007 Ulotaront (SEP-363856) Parkinson’s disease psychosis Phase 2
008 SEP-4199 Bipolar depression Phase 2
013 DSP-3905 Neuropathic pain Phase 1
014 DSP-6745 Parkinson’s disease psychosis Phase 1
015 SEP-378608 Bipolar disorder Phase 1
015 SEP-378614 Treatment resistant depression Phase 1
015 SEP-380135 Agitation in Alzheimer’s disease Phase 1
016 DSP-0038 Alzheimer’s disease psychosis Phase 1